So far this year, the average stock in the Russell 3,000 is up 0.12%. When factoring out Intercept Pharmaceutical's (ICPT) 589% gain already in 2014, however, the average stock in the index is down 0.07% year-to-date.
That's right, ICPT is already up 589.91% in 2014 after gaining 100% in 2013! That's what happens when the Data and Safety Monitoring Board stops the testing of your liver disease drug early because it's working too well!
Below is a list of the Russell 3,000 stocks that are already up more than 20% in 2014. Along with ICPT, two other stocks are already up more than 100% -- Conatus Pharma (CNAT) and Neurocrine Biosciences (NBIX). A common theme stands out in the list below. Almost all of the stocks are from the Health Care sector, and more specifically, the Biotech group.
57.3% of the stocks in the Russell 3,000 are down so far year-to-date. Below is a list of the biggest losers. As shown, Chelsea Therapeutics (CHTP) is down the most with a loss of 45.21%, followed by Cyan (CYNI), support.com (SPRT), BIND Therapeutics (BIND) and Sears Holdings (SHLD). Other notable stocks on the list of 2014's biggest losers include JC Penney (JCP), RadioShack (RSH) and Select Comfort (SCSS). All of the stocks on the list below are down more than 15% so far this year.
Copyright © Bespoke Investment Group
